Review Article
Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?
Table 2
Therapeutic antibodies that are being evaluated in the clinical trials.
| Source | Target | Name | Clinical trial | References |
| Viral | Env CD4 binding site | 3BNC117 | Phase 2a | [43] | Env V3 glycan site | 10-1074 | Phase I | [44] | Env CD4 binding site | VRC01 | Phase I | [45] | V1V2 | PGDM1400 | Phase I | [42] | Env V3 glycan site | PGT121 | Phase I | [46] | Env MPER | 10E8v4 | Phase I | [47] | Env CD4 binding site | N6 | Phase II | [42] |
| Cellular | CCR5 | HGS004 | Phase I | [48] | CCR5 | PRO140 | Phase III | [49] | CCR5/CCR2 | Cenicriviroc | Phase III | [50] | CD4 | TMB-355 | Phase III | [51] | PDL1 | BMS-936559 | Phase I | [52] |
|
|